Actively Recruiting
Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-272 in Healthy Participants
Led by Vertex Pharmaceuticals Incorporated · Updated on 2026-03-31
128
Participants Needed
1
Research Sites
55 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of single and multiple ascending doses of VX-272.
CONDITIONS
Official Title
Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-272 in Healthy Participants
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Body mass index (BMI) of 18.0 to 32.0 kilogram per meter square (kg/m²)
- Total body weight greater than 50 kg
- Male and female participants of non-childbearing potential
You will not qualify if you...
- History of febrile illness or other acute illness not fully resolved within 14 days before first dose
- Any condition possibly affecting drug absorption
- Other protocol defined inclusion/exclusion criteria may apply
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Celerion - Tempe
Tempe, Arizona, United States, 85283
Actively Recruiting
Research Team
M
Medical Information
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
4
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here